Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Microrna-219 in the Central Nervous System: A Potential Theranostic Approach Publisher



Shamaeizadeh N1 ; Mirian M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutics and Novel Drug Delivery Systems Research Centre, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Research in Pharmaceutical Sciences Published:2024


Abstract

Despite the recent therapeutic advances in neurological disorders, curative therapy remains a serious challenge in many cases. Even though recent years have witnessed the development of gene therapy from among the different therapeutic approaches affecting pathophysiological mechanisms, intriguing aspects exist regarding the effectiveness, safety, and mechanism of action of gene therapies. Micro ribonucleic acid (microRNA-miRNA), as a fundamental gene regulator, regulates messenger ribonucleic acid (mRNA) by directly binding through the 3′-untranslated region (3′-UTR). MicroRNA-219 is a specific brain-enriched miRNA associated with neurodevelopmental disorders that play crucial roles in the differentiation of oligodendrocyte progenitorcells, promotion of oligodendrocyte maturation, remyelination, and cognitive functions to the extent that it can be considered a potential therapeutic option for demyelination in multiple sclerosis and spinal cord injury and reverse chronic inflammation pains. Additionally, miR-219 regulates the circadian clock, influencing the duration of the circadian clock period. This regulation can impact mood stability and is associated with phase fluctuations in bipolar patients. Furthermore, miR-219 also plays a role in modulating tau toxicity, which is relevant to the pathophysiology of Alzheimer's disease and schizophrenia. Finally, it reportedly has protective effects against seizures and Parkinson's disease, as well as neoplasms, by inhibiting proliferation, suppressing invasion, and inducing cell death in tumor cells. Exploring the miR-219 molecular pathways and their therapeutic effects on central nervous system disorders and the mechanisms involved, the present review study aims to illustrate how this information may change the future of gene therapy. © 2024 Research in Pharmaceutical Sciences.
Related Docs
View other Related Docs
1. Hydroxychloroquine Effects on Mir-155-3P and Mir-219 Expression Changes in Animal Model of Multiple Sclerosis, Metabolic Brain Disease (2020)
2. Glutathione Targeted Tragacanthic Acid-Chitosan As a Non-Viral Vector for Brain Delivery of Mirna-219A-5P: An in Vitro/In Vivo Study, International Journal of Biological Macromolecules (2022)
3. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
4. Micrornas and Synaptic Plasticity: From Their Molecular Roles to Response to Therapy, Molecular Neurobiology (2022)
5. Direct Conversion of Somatic Cells Towards Oligodendroglial Lineage Cells: A Novel Strategy for Enhancement of Myelin Repair, Journal of Cellular Physiology (2020)
6. The Role of Micrornas in the Pathophysiology of Human Central Nervous System: A Focus on Neurodegenerative Diseases, Ageing Research Reviews (2023)
7. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
8. Development of Α4 Integrin Dna Aptamer As a Potential Therapeutic Tool for Multiple Sclerosis, Journal of Cellular Biochemistry (2019)
Experts (# of related papers)
View all Related Experts
Mina Mirian (8)
Nahid Eskandari (7)
Other Related Docs
9. Crispr Technology: A Versatile Tool to Model, Screen, and Reverse Drug Resistance in Cancer, European Journal of Cell Biology (2023)
10. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
11. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
12. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
13. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
14. Altered Anril Methylation in Epileptic Patients, Journal of Molecular Neuroscience (2021)
15. Melatonin Affects the Expression of Microrna-21: A Mini-Review of Current Evidence, Pathology Research and Practice (2024)
16. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
17. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
18. Microrna: Relevance to Stroke Diagnosis, Prognosis, and Therapy, Journal of Cellular Physiology (2018)
19. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
20. Recent Insights Into the Microrna-Dependent Modulation of Gliomas From Pathogenesis to Diagnosis and Treatment, Cellular and Molecular Biology Letters (2022)
21. Non-Coding Rnas and Brain Tumors: Insights Into Their Roles in Apoptosis, Frontiers in Cell and Developmental Biology (2022)
22. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
23. Unveiling Mesenchymal Stem Cells’ Regenerative Potential in Clinical Applications: Insights in Mirna and Lncrna Implications, Cells (2023)
24. Microrna Profiles in Critically Ill Patients, Current Medicinal Chemistry (2024)
25. A Compound Downregulation of Srrm2 and Mir-27A-3P With Upregulation of Mir-27B-3P in Pbmcs of Parkinson’S Patients Is Associated With the Early Stage Onset of Disease, PLoS ONE (2020)
26. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
27. Targeting Vimentin: A Multifaceted Approach to Combatting Cancer Metastasis and Drug Resistance, Cancer and Metastasis Reviews (2024)
28. The Significant Role of Micrornas in Gliomas Angiogenesis: A Particular Focus on Molecular Mechanisms and Opportunities for Clinical Application, Cellular and Molecular Neurobiology (2023)
29. Circrnas As a Novel Class of Potential Diagnostic Biomarkers in Bipolar Disorders, Current Medicinal Chemistry (2024)
30. Construction and Characterization of Human Embryonic Kidney-(Hek)-293T Cell Overexpressing Truncated Α4 Integrin, Research in Pharmaceutical Sciences (2018)
31. Mir-193B Deregulation Is Associated With Parkinson's Disease, Journal of Cellular and Molecular Medicine (2021)
32. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
33. Mir-574, Mir-499, Mir-125B, Mir-106A, and Mir-9 Potentially Target Tgfbr-1 and Tgfbr-2 Genes Involving in Inflammatory Response Pathway: Potential Novel Biomarkers for Chronic Lymphocytic Leukemia, Pathology Research and Practice (2022)
34. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
35. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
36. Micrornas in Female Infertility: An Overview, Cell Biochemistry and Function (2021)
37. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
38. A Review on Expression and Regulatory Mechanisms of Mir-337-3P in Cancer, Journal of Biomolecular Structure and Dynamics (2024)
39. Identification of Mirna-Mrna Network in Autism Spectrum Disorder Using a Bioinformatics Method, Journal of Molecular Neuroscience (2021)
40. The Potential of Targeting Autophagy-Related Non-Coding Rnas in the Treatment of Alzheimer’S and Parkinson’S Diseases, Cellular and Molecular Neurobiology (2024)
41. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
42. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
43. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
44. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
45. Mirna, Biogenesis and Mechanisms of Regulations, Journal of Isfahan Medical School (2014)
46. Generation of Hbsag Dna Aptamer Using Modified Cell-Based Selex Strategy, Molecular Biology Reports (2021)
47. Microrna in Leukemia: Tumor Suppressors and Oncogenes With Prognostic Potential, Journal of Cellular Physiology (2019)
48. Epigenetics and Common Non Communicable Disease, Advances in Experimental Medicine and Biology (2019)
49. The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2016)
50. Serum-Based Microrna Biomarkers for Major Depression: Mir-16, Mir-135A, and Mir-1202, Journal of Research in Medical Sciences (2018)